Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Months of reporting and rich hospital data portray life in the worst asthma hot spot in one of the worst asthma cities: Baltimore. The medical system knows how to help. But there’s no money in it.
The Affordable Care Act has increased the number of people with insurance, but shopping around for plans puts a burden on patients, especially this year.
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
Court allows state attorneys general to join a pending legal challenge to keep billions in subsidies flowing to consumers and insurers, despite the Trump administration’s resistance.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
The Senate draft bill released Thursday to replace the Affordable Care Act risks creating a high-cost ghetto for those with preexisting conditions or long-term sickness, experts say.
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Expertos en políticas de salud que han analizado el texto del proyecto de salud del Senado, aseguran que la legislación no siempre garantizaría la atención de personas con condiciones preexistentes.